Abstract
Most patients with hepatocellular carcinoma (HCC) also have cirrhosis, an independent cause of death. We considered an alternative definition of tumor-related death in patients with HCC and attempted to validate our definition. Two hundred thirty-seven HCC patients were diagnosed, followed, and died over a 12-year period and were evaluated every 2 months, including their last 6 months of life. We defined death by cancer if there was, in the last 6 months of life, a CT scan increase of >25% in the sum of tumor index lesions’ cross-sectional areas or new onset of, or increase in, either vascular invasion or metastatic disease (Group 1). Patients with stable cancer were considered to have died from any other cause (Group 2). We found that 135 (57%) patients died from cancer progression (Group 1), whereas 102 (43%) patients did not (Group 2). There was a statistically significant difference between Group 1 and Group 2 patients in percentage with bilobar disease (P = 0.03), more than one tumor (P = 0.01), an increase in AFP (P = 0.04), vascular invasion (P = 0.001), and the presence of metastases (P = 0.01). We conclude that 57% of patients with unresectable HCC died as a direct result of cancer progression, but 43% did not. The latter died from complications of their cirrhosis, including sepsis, GI bleeds, and renal failure.
Similar content being viewed by others
References
Varela M, Sala M, Llovet JM, Bruix J (2003) Natural history and prognostic prediction of patients with hepatocellular carcinoma. Aliment Pharmacol Ther 17 (Suppl 2):98–102
Parkin DM, Bray F, Ferlay J, Pisani P (2000) Estimating the world cancer burden: GLOBOCAN. Int J Cancer 94:153–156
Bosch X, Ribes J, Borràs J (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19:271–285
El Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750
Collier J, Sherman M (1998) Screening for hepatocellular carcinoma. Hepatology 27:273–278
Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362(9399):1907–1917
Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519–524
Befeler AS, Di Bisceglie AM (2002) Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 122:1609–1619
Llovet JM, Beaugrand M (2003) Hepatocellular carcinoma: present status and future prospects. J Hepatol 38 (Suppl 1):S136–S149
Bruix J, Sherman M, Llovet JM, et al (2001) Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-EASL Conference. J Hepatol 35:421–430
The Liver Cancer Study Group of Japan (1994) Predictive factors for long-term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 74:2272–2280
Tsukuma H, Hiyama T, Tanaka S, et al (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797–1801
Okuda K, Ohtsuki T, Obata H, et al (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 56:918–928
Kaczynsky J, Hansson G, Wallerstedt W (1995) Metastases in cases with hepatocellular carcinoma in relation to clinicopathologic features of the tumor. Acta Oncol 34(1):43–48
Carr BI (2002) Hepatic artery chemoembolization for advanced-stage HCC: experience of 650 patients. Hepatogastroenterology 49:79–86
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Couto, O.F.M., Dvorchik, I. & Carr, B.I. Causes of Death in Patients with Unresectable Hepatocellular Carcinoma. Dig Dis Sci 52, 3285–3289 (2007). https://doi.org/10.1007/s10620-007-9750-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-007-9750-3